https://orcid.org/0000-0002-3853-5196
References
- Chuanying Genga GY, Wanga H, Wua Y, et al. Deep and full immunoparesis is a poor prognostic factor for newlydiagnosed multiple myeloma patients. Leuk Lymphoma. 2021;62(4):883–890.
- Sørrig R, Klausen TW, Salomo M, et al. Risk factors for infections in newly diagnosed Multiple Myeloma patients: a Danish retrospective nationwide cohort study. Eur J Haematol. 2019;102(2):182–190.
- Kastritis E, Zagouri F, Symeonidis A, for the Greek Myeloma Study Group, et al. Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma. Leukemia. 2014;28(10):2075–2079.
- Heaney JLJ, Campbell JP, Iqbal G, et al. Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials. Leukemia. 2018;32(8):1727–1738.
- Lakshman A, Rajkumar SV, Buadi FK, et al. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer J. 2018;8(6):59.
- Valkovic T, Gacic V, Nacinovic-Duletic A. Multiple Myeloma Index for risk of infection. J Cancer. 2018;9(12):2211–2214.
- González-Calle V, Cerdá S, Labrador J, et al. Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma. Haematologica. 2017;102(5):922–931.
- Vacca A, Melaccio A, Sportelli A, et al. Subcutaneous immunoglobulins in patients with multiple myeloma and secondary hypogammaglobulinemia: a randomized trial. Clin Immunol. 2018;191:110–115.
- Girmenia C, Cavo M, Offidani M, et al. Management of infectious complications in multiple myeloma patients: expert panel consensus-based recommendations. Blood Rev. 2019;34:84–94.
- Renaud L, Schraen S, Fouquet G, et al. Response to pneumococcal vaccination in multiple myeloma. Cancer Med. 2019;8(8):3822–3830.
- Muchtar E, Dispenzieri A, Kumar SK, et al. Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival. Leukemia. 2017;31(1):92–99.